- funding probability score
- total disclosed funding
- last round valuation estimate
- disclosed funding rounds
- latest round
- latest funding stage
- next round estimate
- development stage
- number of investors
- number of competitors
- monthly web visits
- twitter followers
- Pharmaceutical and Biotechnology company developing a new class of anti-cancer drugs with a novel mechanism of action: inhibition of the mTOR1/2 signaling pathways and induction of Autophagy.
Ability Pharmaceuticals is a drug discovery and development company headquartered in Barcelona. Ability Pharmaceuticals idenitfies, licenses and develops innovative, patented, safer human therapeutics targeting cell membranes for cancer therapy and other indications with unmet medical needs characterized by: • Blockbuster potential. • lower risk of drug development and lower development costs (fast track review or orphan drug status). • very high pricing; low cost of goods • low promotional costs in few specialized physicians and centers. Ability Pharmaceuticals is developing lipid derivatives to treat cancer in an innovative therapeutic approach: Lipid Analogue Therapeutics (new mechanism of action). Ability Pharmaceuticalss has a drug candidate ABTL0812 in clinical development (Phase I/ib in advanced cancer patients, started in February 2014), and a second one to start preclinical in 4Q12. Actively acquiring new compounds from academia.
There is much more to this profile.
Log in or sign up for free to see the whole thing.
Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats